MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 05-23-2026
Acer Therapeutics Operating Cash Flow 2011-2026 | ACER
Annual Operating Cash Flow Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.3 M | -135 K | -17 M | -29.5 M | -16.6 M | -14.1 M | - | - | - | -6.13 M | -8.92 M | -4.99 M | -4.38 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -135 K | -30.3 M | -13.2 M |
Quarterly Operating Cash Flow Acer Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -28.9 M | -14.5 M | -9.02 M | - | -22 M | -12.9 M | -3.01 M | - | 1.29 M | 9.24 M | 3.01 M | - | -13.1 M | -8.7 M | -5.07 M | - | -25.5 M | -18.1 M | -9.75 M | - | -12 M | -7.25 M | -3.23 M | - | -9.89 M | -4.76 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.48 M | 429 K | 3.04 M | - | -7.31 M | -5.07 M | -2.19 M | - | -3.47 M | -2.35 M | -791 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.24 M | -28.9 M | -7.39 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 7.42 | 5.55 % | $ 203 M |  Israel |
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-2.67 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.71 | 5.9 % | $ 200 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
456 M | $ 92.36 | 0.24 % | $ 22.3 B | Germany |
 |
AstraZeneca PLC
AZN
|
14.6 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Compugen Ltd.
CGEN
|
31.6 M | $ 2.68 | -4.29 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
28.7 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
-6.05 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.59 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.68 | -5.59 % | $ 31.1 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.13 | -0.16 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
10.5 M | $ 31.34 | -3.84 % | $ 843 M | USA |
 |
Affimed N.V.
AFMD
|
-110 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 22.15 | 2.59 % | $ 287 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
-28 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
-88.6 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-35.1 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Grifols, S.A.
GRFS
|
902 M | $ 8.02 | 0.44 % | $ 5.45 B |  Spain |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-4.77 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-78.2 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
-27.6 M | $ 0.86 | -0.05 % | $ 143 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-483 M | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
11.2 M | $ 14.8 | -0.54 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.47 M | - | 5.93 % | $ 314 M | Canada |
 |
InflaRx N.V.
IFRX
|
-35.3 M | $ 2.73 | 4.62 % | $ 184 M | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.55 | 4.26 % | $ 5.84 M | Israel |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |